1
Clinical Trials associated with Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 vaccine(U S Army Medical Research & Development Command)A Phase 1 Dose Escalating Study of Two Enterotoxigenic Escherichia Coli Prototype Adhesin-based Vaccines With or Without Modified Heat-labile Enterotoxin by Intradermal or Transcutaneous Immunization
The purpose of the study is to determine if immunization with a chimeric E. coli protein, dsc14CfaE-sCT2/LTB5, is safe and immunogenic when administered by vaccination under the skin.
100 Clinical Results associated with Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 vaccine(U S Army Medical Research & Development Command)
100 Translational Medicine associated with Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 vaccine(U S Army Medical Research & Development Command)
100 Patents (Medical) associated with Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 vaccine(U S Army Medical Research & Development Command)
100 Deals associated with Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 vaccine(U S Army Medical Research & Development Command)